Pulmonary hypertension is one of the most feared complications of heart failure with reduced ejection fraction, the condition in which a damaged left ventricle can no longer pump blood efficiently. As pressure backs up into the vessels of the lungs, the right ventricle must work against rising resistance, eventually failing in its own right. Prognosis worsens sharply once this happens, yet therapeutic options remain frustratingly limited. SGLT2 inhibitors such as dapagliflozin and empagliflozin have already transformed heart failure care after large trials demonstrated reduced hospitalizations and cardiovascular deaths, and earlier work, including the EMBRACE-HF trial of empagliflozin, hinted at favorable effects on pulmonary artery pressures. What remained unclear was whether these drugs influence the pulmonary circulation through mechanisms beyond their established hemodynamic and metabolic effects.

To probe that question, the researchers prospectively enrolled seventy-four patients with ischemic heart failure following acute myocardial infarction, all of whom had a high echocardiographic probability of pulmonary hypertension. In this single-center, non-randomized study, forty-two patients received either dapagliflozin or empagliflozin at 10 milligrams per day on top of guideline-directed medical therapy, while thirty-two patients received guideline-directed therapy alone. The design means the findings show association rather than causation, but the investigators compensated by layering on an unusually deep molecular workup, including untargeted plasma proteomics on pooled samples, microRNA profiling, and selected biomarkers of cellular senescence and oxidative stress. Candidate discoveries were then validated with enzyme-linked immunosorbent assays and quantitative reverse-transcription polymerase chain reaction.

The clinical signal was consistent and encouraging. Patients on SGLT2 inhibitors showed improved World Health Organization functional class, meaning they could tolerate more physical activity before symptoms limited them. They also displayed fewer signs of right-heart failure, a reduced echocardiographic probability of pulmonary hypertension, and enhanced coupling between the right ventricle and the pulmonary artery, a key echocardiographic measure of how efficiently the right heart’s pump matches the load imposed by the lung circulation. Right ventricle-pulmonary artery coupling is increasingly recognized as a powerful prognostic marker in heart failure, and its improvement here aligns with recent secondary analyses of randomized trials suggesting that dapagliflozin favorably reshapes right ventricular-vascular interaction.

Beneath these clinical observations lay the study’s most intriguing molecular thread. Proteomic and microRNA analyses revealed that SGLT2 inhibitor therapy was associated with lower circulating activin A and reduced levels of miR-1306-5p, a small regulatory RNA previously linked to vascular smooth muscle proliferation through the SIRT7 pathway. Activin A belongs to the transforming growth factor beta superfamily, a group of signaling proteins that orchestrate tissue repair, fibrosis, and inflammation. Elevated activin A has long been documented in chronic heart failure, where it is thought to promote adverse myocardial remodeling. By contrast, bone morphogenetic protein signaling, particularly through the BMPR2 receptor, acts as a protective counterweight, and loss of BMPR2 function is a classic driver of pulmonary arterial hypertension. The balance between these opposing arms of the BMP/activin/TGF-beta axis may therefore help determine whether pulmonary vessels adapt or deteriorate under pressure.

Recognizing that a non-randomized clinical observation can only go so far, the team turned to experimental models to test whether the drug could actually drive the molecular changes they had observed. In animal models of ischemia-reperfusion injury, empagliflozin reduced activin A, increased BMPR2 expression, and improved post-ischemic ventricular function. Parallel experiments in human pulmonary artery endothelial cells and cardiomyocytes exposed to hypoxia, the low-oxygen conditions that mimic the hostile environment of failing pulmonary circulation, showed similar molecular shifts. The convergence of clinical and laboratory findings on the same signaling pathway is what gives the study its persuasive force, suggesting that activin A suppression is not an incidental biomarker but a plausible mechanistic link between the drug and the improved pulmonary phenotype.

The researchers also gained a hint about how the drug might exert these effects. When they added chloroquine, an inhibitor of autophagy, the cellular recycling process that degrades damaged components, the beneficial molecular changes were partially attenuated. This points to autophagy as a possible intermediary in the signaling cascade, consistent with earlier work by the same group showing that empagliflozin modulates excessive autophagy through the AMPK/GSK3-beta pathway in diabetic cardiomyopathy. Autophagy has emerged as a central theme in both cardiac and pulmonary vascular disease, and age-related decline in this quality-control system is one of the hallmarks of aging biology, which is precisely why the study appears in GeroScience, a journal focused on the molecular mechanisms of aging.

The findings also resonate with a broader therapeutic landscape that is shifting toward the TGF-beta superfamily. Sotatercept, a fusion protein that traps activin and related ligands, recently demonstrated impressive results in a phase 3 trial of pulmonary arterial hypertension, effectively validating activin signaling as a drug target. The new study raises the tantalizing possibility that SGLT2 inhibitors achieve a gentler version of the same effect through endogenous means, dialing down activin A production rather than sequestering the ligand after release. If confirmed, patients already taking these drugs for heart failure or diabetes might be accruing pulmonary vascular benefits that no one had fully appreciated, simply as a byproduct of a prescription they were already filling.

Important caveats remain. The clinical arm was non-randomized and single-center, with a modest sample size, so confounding by indication, disease severity, or co-treatment cannot be excluded, and the pooled proteomic design limits individual-level inference. The authors themselves frame the work as showing that modulation of the BMP/activin/TGF-beta pathway is biologically plausible and consistently associated with SGLT2 inhibitor therapy across complementary models, rather than proving it as the definitive mechanism. Still, the triangulation from patient plasma to animal hearts to hypoxic human cells is exactly the kind of convergent evidence that typically precedes randomized testing. If future trials confirm that SGLT2 inhibitors meaningfully lower pulmonary pressures and improve right-heart outcomes through activin A suppression, a drug class born as a glucose-lowering agent will have added yet another chapter to one of the most remarkable therapeutic repurposing stories in cardiovascular medicine, and patients with the doubly burdened heart-and-lung phenotype of advanced heart failure may gain a new lease on survival.

Subject of Research: SGLT2 inhibitor effects on activin A and BMP/activin signaling in ischemic cardiomyopathy with pulmonary hypertension

Article Title: Sodium-glucose cotransporter 2 inhibitors are associated with reduced circulating activin A and modulation of BMP/activin signaling in ischemic cardiomyopathy with high echocardiographic probability of pulmonary hypertension

Article References: Madonna, R., Del Boccio, P., Borghini, A., Alberti, M., Biondi, F., Cufaro, M. C., Morganti, R., Pieragostino, D., Andreassi, M. G., Rocca, C., Ferdinandy, P., Mattii, L., Angelone, T., & De Caterina, R. (2026). Sodium-glucose cotransporter 2 inhibitors are associated with reduced circulating activin A and modulation of BMP/activin signaling in ischemic cardiomyopathy with high echocardiographic probability of pulmonary hypertension. GeroScience. https://doi.org/10.1007/s11357-026-02497-0

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02497-0

Keywords: SGLT2 inhibitors, pulmonary hypertension, activin A, BMPR2, heart failure, ischemic cardiomyopathy, empagliflozin, dapagliflozin, autophagy, miR-1306-5p, right ventricle, TGF-beta signaling

The research, led by Jia-Lu Yao, Yun Du, Hua-Qian Yang and Ya-Feng Zhou and their colleagues at Soochow University in Suzhou, China, focused on the epigenetic landscape of post-myocardial infarction heart failure, one of the leading causes of death and disability worldwide. Epigenetics refers to chemical tags that sit on top of the genetic code without changing the sequence itself. The most studied of these tags is DNA methylation, the addition of a methyl group to cytosine bases in DNA. When methylation accumulates in the promoter region of a gene, the stretch of DNA that acts as its on-switch, the gene is often shut down, sometimes permanently. The team set out to map exactly which genes are being switched off this way in hearts that have failed after a heart attack.

To do so, the researchers performed reduced representation bisulfite sequencing, a technique that converts unmethylated cytosines into uracils and thereby allows methylation patterns to be read base by base across the genome, alongside RNA sequencing, which measures how actively each gene is being transcribed. They applied both methods to left ventricular tissue from a rat model of post-infarction heart failure. The logic of the approach was simple but powerful: any gene that is both heavily methylated at its promoter and transcriptionally downregulated in the failing heart is a candidate for an epigenetically silenced contributor to disease. Candidate findings were then cross-checked against human datasets from patients with ischemic cardiomyopathy, the form of heart failure that follows blocked coronary arteries.

One gene rose to the top of the integrated analysis: FCGR2A. This gene encodes a receptor for the Fc portion of immunoglobulin G, a protein better known for its roles in immune cells, but one that the study shows is functionally important in cardiomyocytes themselves. In the failing rat hearts, the FCGR2A promoter was hypermethylated and the gene was transcriptionally downregulated. Crucially, the same pattern was conserved in human ischemic cardiomyopathy, meaning the epigenetic silencing observed in the animal model mirrors what happens in failing human hearts. That conservation across species strengthened the case that FCGR2A loss is not a rodent artifact but a genuine feature of the disease.

The functional experiments that followed revealed why losing FCGR2A matters. When the researchers reduced FCGR2A expression in cardiomyocytes exposed to ischemia-hypoxia, the low-oxygen conditions that mimic a heart attack, the cells fared worse: apoptosis, the programmed death of cells, increased, and intracellular calcium accumulated to dangerous levels. Conversely, when FCGR2A was overexpressed, both apoptosis and calcium overload were attenuated. Calcium is the trigger for cardiac contraction, and its concentration inside heart cells is normally controlled with exquisite precision. When that control fails, calcium floods the mitochondria, the energy factories of the cell, and activates the mitochondrial apoptotic pathway, a self-destruct program that dismantles the cell from within.

The mechanistic thread connecting FCGR2A to calcium dysregulation ran through the L-type calcium channel, the main gateway through which calcium enters cardiomyocytes during each heartbeat. The team found that downregulation of FCGR2A enhanced the current density of this channel, effectively widening the gate and letting more calcium pour into the cell with every electrical impulse. The resulting calcium overload then tipped the mitochondria into releasing the signals that execute apoptosis. In this way, the loss of a single epigenetically silenced gene was sufficient to reproduce two of the most damaging features of the remodeling heart: electrical and calcium mishandling, and progressive loss of contractile cells.

But the study did not stop at identifying the victim of methylation; it also identified the culprit. Through further analysis, the researchers pinpointed ATF3, a transcription factor known to be induced by stress signals, as an upstream repressor of FCGR2A. ATF3 binds directly to the FCGR2A promoter and facilitates its hypermethylation, thereby recruiting the epigenetic machinery that silences the gene. This discovery reframes ATF3, often described in the literature as a stress-responsive factor with ambiguous roles, as an active driver of pathological remodeling in the post-infarct heart. The relationship was confirmed by rescue experiments: when the researchers restored FCGR2A expression, the detrimental effects of ATF3 overexpression were reversed, demonstrating that FCGR2A lies downstream of ATF3 in the pathway and that restoring it can compensate for the damage caused by the repressor.

The implications of this ATF3/FCGR2A axis extend in two directions. Diagnostically, FCGR2A methylation or expression levels could serve as a biomarker, a measurable molecular signature indicating how aggressively a heart is remodeling after an infarct, potentially allowing clinicians to identify high-risk patients earlier than current imaging or blood tests allow. Therapeutically, the pathway offers two points of intervention: blocking ATF3’s binding to the FCGR2A promoter, or directly restoring FCGR2A expression. Neither strategy is close to the clinic, and translating epigenetic therapies to the heart remains a formidable challenge, but the study provides a clear molecular target where previously there was only a descriptive picture of remodeling.

The work also carries broader significance for the field of cardiac epigenetics. The epigenetic landscape of post-myocardial infarction heart failure has remained incompletely characterized, and most existing therapies, from beta-blockers to angiotensin receptor blockers, act on signaling pathways rather than on the gene-regulatory programs that lock in the failing state. By combining unbiased genome-wide methylation mapping with transcriptomics and validating in human tissue, the Soochow team has demonstrated a template for discovering other epigenetically silenced genes that may contribute to heart failure. Each such gene is a potential node in the network that converts a survivable heart attack into a progressive, fatal disease.

For the millions of patients who develop heart failure after a heart attack each year, the promise of this research lies in its specificity. Rather than broadly dampening the heart’s workload, a therapy built on the ATF3/FCGR2A axis would aim to prevent the molecular silencing that drives cardiomyocyte death in the first place, preserving the muscle that remains. The study’s authors suggest that FCGR2A represents a potential diagnostic biomarker and therapeutic target for preventing adverse cardiac remodeling. As epigenetic tools such as demethylating agents and targeted gene delivery mature, findings like these will be the roadmap that tells such tools where to go. The failing heart, this work suggests, is not merely a worn-out pump but a genome under mismanagement, and correcting that mismanagement may be the next frontier in cardiovascular medicine.

Subject of Research: Epigenetic regulation of FCGR2A in post-myocardial infarction heart failure

Article Title: Epigenetic silencing of FCGR2A by promoter hypermethylation exacerbates cardiac remodeling in post-myocardial infarction heart failure

Article References: Yao, J.-L., Du, Y., Wang, K.-Y., Wang, H.-J., Yang, H.-Q., & Zhou, Y.-F. (2026). Epigenetic silencing of FCGR2A by promoter hypermethylation exacerbates cardiac remodeling in post-myocardial infarction heart failure. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06410-y

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06410-y

Keywords: heart failure, myocardial infarction, epigenetics, DNA methylation, FCGR2A, ATF3, calcium overload, cardiac remodeling, cardiomyocyte apoptosis, ischemic cardiomyopathy, L-type calcium channel, transcriptional repression